Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; silicon dioxide; sodium acetate; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

henry schein, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

fresenius kabi usa, llc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection, usp is indicated for the following therapeutic uses: • the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.  • the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass.  • the reduction of elevated intraocular pressure when it cannot be lowered by other means.  • the promotion of urinary excretion of toxic substances. mannitol solution, 2.5% is indicated as an irrigation solution in transurethral prostatic resection or other transurethral surgical procedures. • well established anuria due to severe renal disease.  • severe pulmonary congestion or frank pulmonary edema.  • active intracranial bleeding except during craniotomy.  • severe dehydration.  • progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.  • progressive heart failure or pulmonary congestion after mannitol therapy

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol intravenous (mannitol injection, usp) is indicated for the following purposes in adults and pediatric patients. - reduction of intracranial pressure and brain mass. - reduction of high intraocular pressure when the pressure cannot be lowered by other means. measurement of glomerular filtration rate. - well established anuria due to severe renal disease. - severe pulmonary congestion or frank pulmonary edema. - active intracranial bleeding except during craniotomy. - severe dehydration. - progressive heart failure or pulmonary congestion after institution of mannitol therapy. - do not administer to patients with a known hypersensitivity to mannitol. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will dimin

Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - mannitol 15 g/100 ml - solution for infusion - mannitol 150 mg/ml - mannitol

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the following purposes in adults and pediatric patients. therapeutic use reduction of intracranial pressure and brain mass. reduction of high intraocular pressure. diagnostic use measurement of glomerular filtration rate. mannitol injection is contraindicated in patients with: well established anuria due to severe renal disease. severe pulmonary congestion or frank pulmonary edema. active intracranial bleeding except during craniotomy. severe dehydration. progressive heart failure or pulmonary congestion after institution of mannitol therapy. do not administer to patients with a known hypersensitivity to mannitol. 8.1 pregnancy risk summary there are no well-controlled studies in pregnant women that establish developmental toxicity related to the use of mannitol injection. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data). the available data do not establish the presence or absence of developmental toxicity related to the use of mannitol. there are limited animal data in the published literature. the effects of mannitol on embryo-fetal development have not been evaluated; however, fluid shifts occurred in animal studies in response to maternal infusion of mannitol. mannitol injection should be given to a pregnant woman only if clearly needed. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. data human data published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy. 8.2 lactation risk summary lactation studies have not been conducted with mannitol. it is not known whether this drug is excreted in human milk. mannitol injection should be administered to lactating women only if clearly indicated. studies assessing the effects of mannitol injection in breastfed children have not been performed. studies to assess the effect of mannitol on milk production or excretion have not been performed. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mannitol and any potential adverse effects on the breastfed child from mannitol or from the underlying maternal condition. 8.5 geriatric use mannitol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in elderly patients with impaired renal function. evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of mannitol [see warnings and precautions (5)]. 8.6 renal impairment patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure with administration of mannitol. evaluate the renal, cardiac and pulmonary status of the patient and correct fluid and electrolyte imbalances prior to administration of mannitol [see warnings and precautions (5)].

Израел - Енглески - Ministry of Health

a.l. medi-market ltd. - mannitol - solution for infusion - mannitol 200 g / 1000 ml - mannitol - mannitol 20% imuna, solution for infusion is indicated for: - the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established;- the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; - the reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mannitol, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - osmitrol intravenous infusion (mannitol intravenous infusion, bp) can be used in: the promotion of diuresis in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; the reduction of intraocular pressure when the pressure cannot be lowered by other means; the reduction of intracranial pressure and treatment of cerebral oedema by reducing brain mass and; promoting the urinary excretion of toxic substances.

Канада - Енглески - Health Canada

fresenius kabi canada ltd - mannitol - solution - 25% - mannitol 25% - osmotic diuretics

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium phosphate; magnesium stearate; gelatin; purified talc; wheat starch; lactose monohydrate - ritalin 10 tablets and ritalin la capsules are indicated for the treatment of adhd. ritalin 10 tablets are also indicated for the treatment of narcolepsy. attention-deficit hyperactivity disorder (adhd) adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children. ritalin 10 / ritalin la are indicatedas an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. special diagnostic considerations for adhd in children: the aetiology of this syndrome is unknown and there is no single diagnostic test.